Actinium Pharma

ATNM

1.4007.89% ( -0.120 )

Closed: Oct 26, 16:00:00 (EDT)

Current ValuationThe current P/E ratio is 3.89, above the reasonable range, cheaper than 0.51% of the time in the past 3 years, and the industry ranks 18/606, the industry Median -1.86.

3.89xP/E

Stock price$1.40Earnings per share$0.36

Historical Valuation

P/E ratioTypical rangeMedian

Peer P/E ratio Comparison

It displays how the company's P/E ratio compares to top companies within its industry.

021426384

The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.

Industry P/E ratio Comparison

This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.

0x30x60x90x120x150x

P/E ratio
Name/Symbol
INCYUSIncyte	14.24x	72.02%	$22.97B
GRFSUSGRIFOLS SA	10.39x	45.10%	$5.45B
ACADUSAcadia Pharma	8.94x	73.21%	$3.40B
BVNRYUSBavarian Nordic A/S	11.79x	--	$2.82B
NRIXUSNurix Therapeutics	9.47x	191.12%	$2.79B
PURRUSHyperliquid Strategies	9.85x	67.60%	$2.52B
ADMAUSAdma Biologics	14.67x	35.42%	$2.48B
AUPHUSAurinia Pharma	7.22x	54.20%	$2.27B
LKFTUSLakefront Biotherapeutics	2.94x	86.45%	$2.03B
ANABUSAnaptysbio	5.57x	1,003.56%	$1.46B
VORUSVor BioPharma	1.73x	89.71%	$1.08B
RIGLUSRigel Pharma	2.90x	83.91%	$932.31M
MGTXUSMeiraGTx	11.16x	122.03%	$881.67M
ABUSUSArbutus Pharma	5.40x	535.59%	$827.15M
IRWDUSIronwood Pharma	4.45x	715.55%	$578.34M
AGENUSAgenus	3.02x	--	$277.33M
QTTBUSQ32 Bio	7.45x	162.04%	$251.55M
CUVLUSClinuvel Pharmaceuticals	10.89x	--	$250.12M
PLXUSProtalix Biotherap	10.55x	400.00%	$199.82M
CGENUSCompugen	5.05x	173.68%	$177.61M

Risk Warning

Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.